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(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, 




1st Editorial Decision 20th Dec 2018 
Thank you for submitting your manuscript to The EMBO Journal. Your study has now been seen by 
two referees and their comments are provided below.  
 
Both referees find the analysis interesting, but they also indicate that further analysis is required. In 
particular the referees find that further data is needed to support a causal role of Prx4 activity in 
inflammatory signalling and where it fits in the pathway. Also referee #2 is asking for more insight 
into how Prx4 and caspase-1 end up in the same vesicles. Both points raised are reasonable. For the 
point regarding how Prx4 and caspase-1 meet, we don't need the complete mechanism but some 
additional insight would be good.  
 
Should you be able to address the raised concerns, then I would like to invite you to submit a revised 
version. I should add that it is EMBO Journal policy to allow only a single major round of revision, 






Referee #1:  
 
 
General summary and opinion about the principle significance of the study, its questions and 
findings  
The significance of this work is contextualized within a widely contentious area concerning the 
mechanism of IL-1β secretion and its subsequent cell to cell signaling. Specifically, the work aims 
to support a model wherein Peroxiredoxin-4 (Prdx4) directly regulates Caspase-1 activity within 
extracellular vesicles (EVs) to control IL-1β maturation. While the submitted work does clearly 
support a role for Prdx4 in inflammatory signaling using genetics, the biochemical insights provided 
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are without strong experimental support. One major limitation of the work is a robust demonstration 
that Prdx4 acts downstream of Caspase-1. Accurately positioning Prdx4 at this step is critical for 
maintaining its proposed mechanism of action.  
 
Specific major concerns essential to be addressed to support the conclusions:  
 
Many of the experimental data used by Lipinski et al. to support their model rely almost exclusively 
on NLRP3 mediated Caspase-1 activation. Inflammasome signaling driven by NLRP3 is unique 
amongst other PRRs owing to its regulation by two distinct signals. The first signal, also known as 
priming, is responsible for inducing the expression of both NLRP3 and pro-IL-1β, while the second 
signal triggers NLRP3 inflammasome assembly (eg. ATP and Nigericin). Priming is positively 
regulated by NFκB signaling, a pathway known to be negatively regulated by Prdx4. The authors do 
address priming defects as a consequence of Prdx4 deficiency, but they limit their analysis 
prematurely to the transcriptional level.  
It remains possible that Prdx4 may negatively regulate NLRP3 at the protein level. To examine this 
possibility, the authors are encouraged to demonstrate that Prdx4 does not impinge on NLRP3 
protein levels and or stability.  
From this point, the study takes a dramatic shift to support a secretory role for Prdx4 in regulating 
Caspase-1 activity inside extracellular vesicles. The authors begin to support this model first by 
showing that Prdx4 is secreted into the tissue culture (TC) supernatant upon NLRP3 activation using 
ATP. Even though the secretion of Prdx4 is shown to require Caspase-1 activation (YVAD blocks 
Prdx4 secretion), no experimental support is provided to rule out alternative modes of non-vesicular 
secretion. This is peculiar given the authors cite alternative modes of secretion for IL-1β itself (eg. 
Gasdermin D pores, passive loss of cellular integrity upon pyroptotic cell-death etc.).  
Nonetheless, this observation prompts the investigators to examine the TC-supernatant for evidence 
of extracellular vesicles (EVs) citing previous studies showing ATP stimulation permits non-
conventional vesicle shedding. Strangely, no attempt is made to test whether vesicle shedding is 
observed in response to other NLRP3 agonists, or by different inflammasome sensors (AIM2 or 
NLRC4). This is critical for supporting the earlier data showing the phenotype accompanying Prdx4 
deletion is independent of inflammasome identity. Notwithstanding, the TEM data used to support 
EV isolation is of poor quality. What's more, no orthogonal technique is used to unequivocally prove 
EVs have been isolated (eg. Dynamic Light Scattering). Although CD63 is used as a marker to 
confirm isolation of EVs, no markers serving as negative controls are included. Mature IL-1β in EV 
preparations is undetected, which prompts evaluation of their bioactivity in assays downstream of 
the IL-1β receptor. No measure, however, is taken to control for the relative dose of administered 
EV preparations.  
In the final two figures, Lipinski et al. provide experimental support for a direct interaction between 
Prdx4 and Caspase-1 using recombinant protein or heterologous expression in 293T cells. 
Specifically, the association between Prdx4 and Caspase-1 is attributed to disulfide bond exchange. 
Perhaps this is expected since Prdx4 is known to mediate disulfide bond formation in the 
endoplasmic reticulum through successive rounds of oxidation-reduction. Thus, disulfide bond 
exchange is unlikely to display specificity given access to an alternative client protein. Nevertheless, 
exchange reactions could benefit from inclusion of a negative control. Since the site of exchange is 




Referee #2:  
 
The paper considers the role of Prx4 in the inflammasome-mediated immune response by analysing 
the effect of Prx4 KO on a variety of measures of response. The data demonstrates a clear phenotype 
of KO but falls short of a clear understanding of the link between cause and affect. The function of 
Prx4 is to reduce peroxides. Its absence will inevitably lead to an increase in peroxides generated in 
the ER. In addition no attempt is made to resolve how Prx4 (an ER protein) and caspase1 (a 
cytosolic protein) end up in exosomal vesicles. It is actually not clear that they are co-localised in 
these vesicles as stated by the authors as there is no evidence presented that they are both present in 
the same vesicle. Without these questions being addressed the paper provides a general observation 
but does not provide any mechanistic insight into how Prx4 could control the immune response.  
There are some very basic inaccuracies in the paper when the authors evaluate the form of Prx4 the 
interacts with caspase1. They infer a monomer, dimer, decamer transition from studying the banding 
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patterns by SDSPAGE. It is highly likely that Prx4 remains as a decamer throughout this process. 
What the authors are actually analysing is the denatured protein and the reduction of disulfides 
which would covalently link the individual subunits so that they form dimer or decamers under 
denaturing conditions. There is actually no evidence presented that suggests Prx4 subunits dissociate 
from a decamer under reducing conditions. For this analysis they would need to determine the 
oligomeric status under native conditions by for example size exclusion chromatography or sucrose 
gradient analysis. The specifity they do see between reduced and oxidised Prx4 is most likely due to 
a disulfide being formed between the resolving thiol in Prx4 and a thiol in caspase1.  
In summary, the work is lacking a link between cause and affect, does not demonstrate a link 
between Prx4 activity and the phenotypes they see and the work should be supported by some 




1st Revision - authors' response 24th May 2019 
Referee #2:  
 
The paper considers the role of Prx4 in the inflammasome-mediated immune response by analysing 
the effect of Prx4 KO on a variety of measures of response. The data demonstrates a clear phenotype 
of KO but falls short of a clear understanding of the link between cause and affect.  
1. The function of Prx4 is to reduce peroxides. Its absence will inevitably lead to an increase in 
peroxides generated in the ER. In addition no attempt is made to resolve how Prx4 (an ER protein) 
and caspase1 (a cytosolic protein) end up in exosomal vesicles. It is actually not clear that they are 
co-localised in these vesicles as stated by the authors as there is no evidence presented that they are 
both present in the same vesicle. Without these questions being addressed the paper provides a 
general observation but does not provide any mechanistic insight into how Prx4 could control the 
immune response.  
Response: We would like to thank for this useful comment, which has clearly helped us to improve 
our manuscript.  To elucidate how Prdx4 and caspase-1 end up in extracellular vesicles, we 
performed several additional experiments. We now show this data combined with previous data in 
Figure 5 and have restructured the manuscript accordingly (lines 249-260 and 268-287). We first 
performed cellular fractionation and observed that Prdx4 is present in the cytosolic compartment, 
which is in accordance with literature (Jin, Chae et al., 1997, Tavender, Sheppard et al., 2008) and 
database predictions, also including EV contents (Pathan, Fonseka et al., 2019, UniProt Consortium, 
2018). Cytosolic levels increased in response to inflammasome activation (Figure 5A). This 
suggested that a proportion of Prdx4 is contained in the cytosol, where it is thus able to interact with 
caspase-1. Cytosolic proteins can be sorted and sequestered into multivesicular bodies (MVB) in an 
ESCRT-complex-dependent manner (Babst et al., 2002, Teis et al., 2008) and released as cargo from 
MVBs  as extracellular vesicles (TheryWitwer et al., 2018, Tkach & Thery, 2016). Thus, we 
blocked the release of mature extracellular vesicles from MVBs using the inhibitor GW4869 
(Trajkovic, Hsu et al., 2008, Kosaka et al., 2010, Mittelbrunn et al., 2011). Indeed, we found that 
GW4869 significantly lowered Prdx4 as well as caspase-1 secretion (Figure 5F). To strengthen the 
conclusion that that cytosolic Prdx4 together with cytosolic caspase-1 might be sorted into MVBs 
and released via EVs from the cell, we then rearranged out data, showing that Prdx4 was enriched in 
CD63+ fractions, a marker for MVBs (Kobayashi, Vischer et al., 2000) (Figure 5G and H). 
Moreover, these fractions were also positive for ASC, pro-caspase-1 and pro-IL-1b. Thus, these 
results provide evidence that Prdx4 and caspase-1 are co-present in MVBs, suggesting their joint 
release from inflammasome-activated cells. 
We have also performed new experiments to investigate whether Prdx4 and caspase-1 are co-
localized within the same vesicle. To this end, we used immunofluorescence microscopy as 
previously described for EVs (Athman, Wang et al., 2015). Our new set of data is now displayed in 
Appendix Figure S6. We observed a high degree of co-localization for EVs derived from 
LPS+ATP stimulated BMDMs that were stained for Prdx4 and caspase-1 and counterstained with a 
lipophilic dye for the EV membrane (text in lines 319-325).  
Collectively, these data indicate that distinct EV populations are released in response to NLRP3 
inflammasome activation, containing constituents of the inflammasome as well as Prdx4. 
 
2. There are some very basic inaccuracies in the paper when the authors evaluate the form of Prx4 
the interacts with caspase1. They infer a monomer, dimer, decamer transition from studying the 
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banding patterns by SDS-PAGE. It is highly likely that Prx4 remains as a decamer throughout this 
process. What the authors are actually analysing is the denatured protein and the reduction of 
disulfides which would covalently link the individual subunits so that they form dimer or decamers 
under denaturing conditions. There is actually no evidence presented that suggests Prx4 subunits 
dissociate from a decamer under reducing conditions. For this analysis they would need to determine 
the oligomeric status under native conditions by for example size exclusion chromatography or 
sucrose gradient analysis. The specifity they do see between reduced and oxidised Prx4 is most 
likely due to a disulfide being formed between the resolving thiol in Prx4 and a thiol in caspase1.  
Response: We apologize for the obvious inaccuracies in the visualization and text of the previous 
version, which referred to the oligomeric state of Prdx4. We fear that this might have led to a 
misunderstanding and we thank the reviewer for pointing this out.  
It was never our intention to infer a monomer, dimer, decamer transition of Prdx4. Rather, we agree 
with the reviewer’s argument that Prdx4 presumably remains a decamer throughout the process. In 
fact, this is supported by the former Figure 5B and C, now Figure 4A and B, showing that the 
majority of Prdx4 is present as a high MW oligomer. We suspect that our former Figure 5A was 
misleading and caused the reviewers scepticism. Our original intention to show this picture of an 
SDS-PAGE loaded with in vitro reduced and non-reduced forms of Prdx4 was to familiarize the 
reader with the multimeric structure of Prdx4 and to determine the electrophoretic properties of the 
oligomers and the monomer of Prdx4. We are aware of the fact that this migration pattern is due to 
denaturing conditions of the SDS-PAGE. We have now removed the picture of the SDS-PAGE and 
the graphical illustration of Prdx4 and deleted the misleading statement (in the former manuscript 
lines 245-247). We have carefully rephrased the respective paragraphs and tuned down claims about 
the exact oligomer structure (“high molecular weight oligomer”), which we only infer from 
literature to be a decamer.   
Our main point, however, is to emphasize our finding (Figure 4A) that caspase-1 co-migrates with 
the Prdx4 oligomer, which was the starting point for the subsequent analysis. We have now inserted 
additional data including recombinant GAPDH as a control for specificity (please see also response 
4 to referee#1). GAPDH was chosen because of its localization in the cytosol and because it 
contains an active-site cysteine, known to be redox-sensitive (Nakajima et al., 2009). However, co-
incubation with Prdx4 had no impact on the distribution and migration patterns of the 
homotetrameric rGAPDH (Appendix Figure S5B), indicating that disulfide bond exchange between 
caspase-1 and Prdx4 is not necessarily unspecific (lines 208-212) and, indeed, most likely occurs 
between one thiol of Prdx4 and the free thiol in caspase-1. We also performed native gel 




Figure I. Native gel electrophoresis and Western blot analysis of rCASP-1 and rPRDX4 that were 
incubated either individually or co-incubated as indicated. 
However, what we also found is that the presence of caspase-1 alters the SDS-PAGE migration 
pattern, of Prdx4 upon their co-incubation in vitro and ii) co-expression in cells, when analysed 
under non-reducing and denaturing conditions (Figure 4A and B) as well as non-reducing + non-
denaturing conditions (Figure I, not included in manuscript). At this point, we can only speculate 
that the appearance of this lower molecular weight band of Prdx4 at the expected size of the reduced 
dimer, are indeed dimers. Although a redox-dependent Prdx4 decamer-to-dimer transitions has been 
demonstrated before (Tavender & Bulleid, 2010, Tavender, Springate et al., 2010), we refrain from 
claiming that these bands are indeed dimers that were released from high-molecular weight 
complexes, as much more detailed experiments would be needed to show the exact structure and 
conditions of the transition. As in fact this point is less relevant for the biological interpretation of 
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our main findings, we have not included Figure I and carefully tuned down our statements (lines 
346-351 in the former manuscript).  
In summary, the work is lacking a link between cause and affect, does not demonstrate a link 
between Prx4 activity and the phenotypes they see and the work should be supported by some 
mechanistic framework to explain how the proteins actually meet each other.  
 
We appreciate the reviewer´s criticism, which has led to a series of rewarding experiments for 
deeper mechanistic exploration. In our view, we now present a compelling set of novel data and 
hope to meet the reviewer’s expectations. 
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2nd Editorial Decision 19th Jun 2019 
Thank you for submitting your revised manuscript to The EMBO Journal. Your study has now been 
seen by the two referees. As you can see below, both referees appreciate the introduced changes and 
support publication here.  
 
Referee #2 has one remaining issue that should be sorted out and that is concerning the sub-cellular 
location of Prx4. Can you please carefully check the cited references and make sure that you 
describe the literature is a good manner. Also, please make sure that you describe how you did the 
experiments in Figure 5A.  
 






Referee #1:  
 
All concerns adequately addressed.  
 
 
Referee #2:  
 
The manuscript is much improved but I am very frustrated by a lack of clarity in the experiments 
aimed at resolving the sub-cellular location of Prx4. I have looked carefully at the past literature 
cited by the authors but see no definitive evidence that the protein is located in the cytosol. The first 
paper Jin et al 1997 fig. 5B notes localisation in what they call a cytosolic fraction but this is 
essentially everything that is not in a nuclear fraction and so could contain ER proteins. The second 
paper, Tavender et al, 2008 shows by immunofluorescence that the protein is localised to the ER 
(Fig. 2). The way these papers are refered to is therefore quite misleading (lines 253-256). The 
authors own data (Fig. 5A) shows Prx4 in both a cytosolic and an insoluble fraction. However, I 
failed to find anywhere in their figure legend or the methods how these fractions were generated 
which is obviously important information. They have a section in the methods on subcellular 
fractionation but that specifically refers to the density gradient analysis. Hence I would like to see 




2nd Revision - authors' response 5th Aug 2019 
Reply to comments @ EMBOJ-2018-101266R  “Prdx4 limits caspase-1 activation and restricts 
inflammasome-mediated signaling by extracellular vesicles” by Lipinski et al. 
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“Thank you for submitting your revised manuscript to The EMBO Journal. Your study has now been 
seen by the two referees. As you can see below, both referees appreciate the introduced changes and 
support publication here.  
 
Referee #2 has one remaining issue that should be sorted out and that is concerning the sub-cellular 
location of Prx4. Can you please carefully check the cited references and make sure that you 
describe the literature is a good manner. Also, please make sure that you describe how you did the 
experiments in Figure 5A. “ 
 
We took care of all editorial comments. All changes in the manuscript have been highlighted in 
blue.  
When preparing the source data files, we found two unintentionally inserted errors: i) The blot in 
Figure 3C was lacking a horizontal line indicating splicing of the blot. The original source data file 
showing the complete including the irrelevant lanes has been uploaded. ii) In Figure 5A, the 
molecular weight marker for Prdx4 indicated 120 kDa instead of 25 kDa. We apologize for these 
inaccuracies and have now corrected these mistakes. 
 
 
Referee #1:  
 
All concerns adequately addressed.  
 
 
Referee #2:  
 
The manuscript is much improved but I am very frustrated by a lack of clarity in the experiments 
aimed at resolving the sub-cellular location of Prx4. I have looked carefully at the past literature 
cited by the authors but see no definitive evidence that the protein is located in the cytosol. The first 
paper Jin et al 1997 fig. 5B notes localisation in what they call a cytosolic fraction but this is 
essentially everything that is not in a nuclear fraction and so could contain ER proteins. The second 
paper, Tavender et al, 2008 shows by immunofluorescence that the protein is localised to the ER 
(Fig. 2). The way these papers are refered to is therefore quite misleading (lines 253-256). The 
authors own data (Fig. 5A) shows Prx4 in both a cytosolic and an insoluble fraction. However, I 
failed to find anywhere in their figure legend or the methods how these fractions were generated 
which is obviously important information. They have a section in the methods on subcellular 
fractionation but that specifically refers to the density gradient analysis. Hence I would like to see 
this point cleared up so that the reader can make up their own minds as to the validity of the claims 
made. 
Reply:  
We appreciate the reviewer´s feedback and apologize for the lack of clarity.  
We have addressed the comment in several ways to increase transparency and to allow a fair 
assessment of the observations by the reader. (1) We have inserted the detailed experimental 
procedure of the cell fractionation in the material and methods part (lines 628-635). To obtain the 
cytosolic fraction, we treated the cells with a hypotonic lysis buffer cells followed by mechanical 
disruption and 2 centrifugation steps (10 min at 1,000×g and 30 min at 20,000×g). The pellet of the 
second step was used as “insoluble fraction”. This is a slight modification of the protocol by Song et 
al., Proteomics 2006. Of course, we cannot completely rule out that smaller quantities of selected 
ER proteins may still be present in this fraction. (2) We thus have carefully rephrased the section on 
past literature and cite two systematic proteomics/immunofluorescence studies, which are suggestive 
of a pool of cytosolic Prdx4 (Itzhak et al., 2016 Elife and Thul et al., Science 2017). We, however, 
now also clearly state that the majority of Prdx4 can be found in the ER, which we never put into 
question. (3) We have added another sentence stating the complexity of the compartmentalization of 
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3rd Editorial Decision 21st Aug 2019 
Thanks for submitting your revised manuscript to The EMBO Journal. I have now had a chance to 
take a look at everything and I am pleased to accept the manuscript for publication here. 
 





























" common	  tests,	  such	  as	  t-­‐test	  (please	  specify	  whether	  paired	  vs.	  unpaired),	  simple	  χ2	  tests,	  Wilcoxon	  and	  Mann-­‐Whitney	  
tests,	  can	  be	  unambiguously	  identified	  by	  name	  only,	  but	  more	  complex	  techniques	  should	  be	  described	  in	  the	  methods	  
section;
" are	  tests	  one-­‐sided	  or	  two-­‐sided?
" are	  there	  adjustments	  for	  multiple	  comparisons?
" exact	  statistical	  test	  results,	  e.g.,	  P	  values	  =	  x	  but	  not	  P	  values	  <	  x;
" definition	  of	  ‘center	  values’	  as	  median	  or	  average;
" definition	  of	  error	  bars	  as	  s.d.	  or	  s.e.m.	  
1.a.	  How	  was	  the	  sample	  size	  chosen	  to	  ensure	  adequate	  power	  to	  detect	  a	  pre-­‐specified	  effect	  size?
1.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  sample	  size	  estimate	  even	  if	  no	  statistical	  methods	  were	  used.
2.	  Describe	  inclusion/exclusion	  criteria	  if	  samples	  or	  animals	  were	  excluded	  from	  the	  analysis.	  Were	  the	  criteria	  pre-­‐
established?
3.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  when	  allocating	  animals/samples	  to	  treatment	  (e.g.	  
randomization	  procedure)?	  If	  yes,	  please	  describe.	  
For	  animal	  studies,	  include	  a	  statement	  about	  randomization	  even	  if	  no	  randomization	  was	  used.
4.a.	  Were	  any	  steps	  taken	  to	  minimize	  the	  effects	  of	  subjective	  bias	  during	  group	  allocation	  or/and	  when	  assessing	  results	  
(e.g.	  blinding	  of	  the	  investigator)?	  If	  yes	  please	  describe.
4.b.	  For	  animal	  studies,	  include	  a	  statement	  about	  blinding	  even	  if	  no	  blinding	  was	  done
5.	  For	  every	  figure,	  are	  statistical	  tests	  justified	  as	  appropriate?
Do	  the	  data	  meet	  the	  assumptions	  of	  the	  tests	  (e.g.,	  normal	  distribution)?	  Describe	  any	  methods	  used	  to	  assess	  it.
Is	  there	  an	  estimate	  of	  variation	  within	  each	  group	  of	  data?
Is	  the	  variance	  similar	  between	  the	  groups	  that	  are	  being	  statistically	  compared?
Yes.
Yes,	  we	  performed	  all	  analyses	  using	  prism	  software.	  We	  described	  the	  statistical	  methods	  in	  the	  
the	  figure	  legends	  and	  the	  material	  and	  methods	  section.
Yes,	  we	  presented	  every	  data	  as	  mean	  +/-­‐	  standard	  deviation.
Yes.
YOU	  MUST	  COMPLETE	  ALL	  CELLS	  WITH	  A	  PINK	  BACKGROUND	  #
We	  chose	  the	  sample	  size	  for	  in	  vivo	  and	  in	  vitro	  experiments	  based	  on	  previous	  experiments.	  The	  
number	  of	  independent	  experiments	  and	  technical	  replicates	  is	  indicated	  in	  the	  respective	  figure	  
legends.	  
The	  envisaged	  number	  of	  animals	  and	  group	  size	  of	  n	  =	  10	  is	  for	  statistical	  hedging	  with	  1.	  
Probability	  of	  error	  1.	  Type:	  0.05	  (5%)	  2.	  	  Desired	  statistical	  power	  of	  0.8	  3.	  Variance	  or	  effect	  
strength	  (indicating	  the	  parameter	  used,	  the	  effect	  intensity	  according	  to	  Cohen)	  d	  =	  1.4	  (effect	  
intensity	  according	  to	  Cohen).
No	  aminals	  or	  samples	  were	  excluded.
We	  selected	  male	  mice	  that	  were	  randomly	  distributed	  in	  different	  groups.
We	  did	  not	  use	  a	  specific	  method	  for	  randomization
We	  	  divided	  anminals	  randomly	  into	  different	  groups.	  We	  assured	  that	  measurements	  (e.g.	  weight	  
measurements)	  were	  preformed	  according	  to	  the	  four	  eyes	  principle.
We	  used	  blinded	  genotypes	  for	  the	  initial	  experiment	  investigating	  the	  genotype-­‐dependent	  effect	  
in	  response	  to	  the	  LPS-­‐induced	  septic	  shock	  (Figure	  1A).	  For	  subsequent	  experimens,	  no	  blinding	  
was	  used.
1.	  Data
the	  data	  were	  obtained	  and	  processed	  according	  to	  the	  field’s	  best	  practice	  and	  are	  presented	  to	  reflect	  the	  results	  of	  the	  
experiments	  in	  an	  accurate	  and	  unbiased	  manner.
figure	  panels	  include	  only	  data	  points,	  measurements	  or	  observations	  that	  can	  be	  compared	  to	  each	  other	  in	  a	  scientifically	  
meaningful	  way.
graphs	  include	  clearly	  labeled	  error	  bars	  for	  independent	  experiments	  and	  sample	  sizes.	  Unless	  justified,	  error	  bars	  should	  
not	  be	  shown	  for	  technical	  replicates.
if	  n<	  5,	  the	  individual	  data	  points	  from	  each	  experiment	  should	  be	  plotted	  and	  any	  statistical	  test	  employed	  should	  be	  
justified
the	  exact	  sample	  size	  (n)	  for	  each	  experimental	  group/condition,	  given	  as	  a	  number,	  not	  a	  range;
Each	  figure	  caption	  should	  contain	  the	  following	  information,	  for	  each	  panel	  where	  they	  are	  relevant:
2.	  Captions
The	  data	  shown	  in	  figures	  should	  satisfy	  the	  following	  conditions:
Source	  Data	  should	  be	  included	  to	  report	  the	  data	  underlying	  graphs.	  Please	  follow	  the	  guidelines	  set	  out	  in	  the	  author	  ship	  
guidelines	  on	  Data	  Presentation.
Please	  fill	  out	  these	  boxes	  #	  (Do	  not	  worry	  if	  you	  cannot	  see	  all	  your	  text	  once	  you	  press	  return)
a	  specification	  of	  the	  experimental	  system	  investigated	  (eg	  cell	  line,	  species	  name).
C-­‐	  Reagents
B-­‐	  Statistics	  and	  general	  methods
the	  assay(s)	  and	  method(s)	  used	  to	  carry	  out	  the	  reported	  observations	  and	  measurements	  
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  being	  measured.
an	  explicit	  mention	  of	  the	  biological	  and	  chemical	  entity(ies)	  that	  are	  altered/varied/perturbed	  in	  a	  controlled	  manner.
a	  statement	  of	  how	  many	  times	  the	  experiment	  shown	  was	  independently	  replicated	  in	  the	  laboratory.
Any	  descriptions	  too	  long	  for	  the	  figure	  legend	  should	  be	  included	  in	  the	  methods	  section	  and/or	  with	  the	  source	  data.
	  
In	  the	  pink	  boxes	  below,	  please	  ensure	  that	  the	  answers	  to	  the	  following	  questions	  are	  reported	  in	  the	  manuscript	  itself.	  
Every	  question	  should	  be	  answered.	  If	  the	  question	  is	  not	  relevant	  to	  your	  research,	  please	  write	  NA	  (non	  applicable).	  	  
We	  encourage	  you	  to	  include	  a	  specific	  subsection	  in	  the	  methods	  section	  for	  statistics,	  reagents,	  animal	  models	  and	  human	  
subjects.	  	  
definitions	  of	  statistical	  methods	  and	  measures:
a	  description	  of	  the	  sample	  collection	  allowing	  the	  reader	  to	  understand	  whether	  the	  samples	  represent	  technical	  or	  
biological	  replicates	  (including	  how	  many	  animals,	  litters,	  cultures,	  etc.).
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Reporting	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This	  checklist	  is	  used	  to	  ensure	  good	  reporting	  standards	  and	  to	  improve	  the	  reproducibility	  of	  published	  results.	  These	  guidelines	  are	  
consistent	  with	  the	  Principles	  and	  Guidelines	  for	  Reporting	  Preclinical	  Research	  issued	  by	  the	  NIH	  in	  2014.	  Please	  follow	  the	  journal’s	  
authorship	  guidelines	  in	  preparing	  your	  manuscript.	  	  
PLEASE	  NOTE	  THAT	  THIS	  CHECKLIST	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6.	  To	  show	  that	  antibodies	  were	  profiled	  for	  use	  in	  the	  system	  under	  study	  (assay	  and	  species),	  provide	  a	  citation,	  catalog	  
number	  and/or	  clone	  number,	  supplementary	  information	  or	  reference	  to	  an	  antibody	  validation	  profile.	  e.g.,	  
Antibodypedia	  (see	  link	  list	  at	  top	  right),	  1DegreeBio	  (see	  link	  list	  at	  top	  right).
7.	  Identify	  the	  source	  of	  cell	  lines	  and	  report	  if	  they	  were	  recently	  authenticated	  (e.g.,	  by	  STR	  profiling)	  and	  tested	  for	  
mycoplasma	  contamination.
*	  for	  all	  hyperlinks,	  please	  see	  the	  table	  at	  the	  top	  right	  of	  the	  document
8.	  Report	  species,	  strain,	  gender,	  age	  of	  animals	  and	  genetic	  modification	  status	  where	  applicable.	  Please	  detail	  housing	  
and	  husbandry	  conditions	  and	  the	  source	  of	  animals.
9.	  For	  experiments	  involving	  live	  vertebrates,	  include	  a	  statement	  of	  compliance	  with	  ethical	  regulations	  and	  identify	  the	  
committee(s)	  approving	  the	  experiments.
10.	  We	  recommend	  consulting	  the	  ARRIVE	  guidelines	  (see	  link	  list	  at	  top	  right)	  (PLoS	  Biol.	  8(6),	  e1000412,	  2010)	  to	  ensure	  
that	  other	  relevant	  aspects	  of	  animal	  studies	  are	  adequately	  reported.	  See	  author	  guidelines,	  under	  ‘Reporting	  
Guidelines’.	  See	  also:	  NIH	  (see	  link	  list	  at	  top	  right)	  and	  MRC	  (see	  link	  list	  at	  top	  right)	  recommendations.	  	  Please	  confirm	  
compliance.
11.	  Identify	  the	  committee(s)	  approving	  the	  study	  protocol.
12.	  Include	  a	  statement	  confirming	  that	  informed	  consent	  was	  obtained	  from	  all	  subjects	  and	  that	  the	  experiments	  
conformed	  to	  the	  principles	  set	  out	  in	  the	  WMA	  Declaration	  of	  Helsinki	  and	  the	  Department	  of	  Health	  and	  Human	  
Services	  Belmont	  Report.
13.	  For	  publication	  of	  patient	  photos,	  include	  a	  statement	  confirming	  that	  consent	  to	  publish	  was	  obtained.
14.	  Report	  any	  restrictions	  on	  the	  availability	  (and/or	  on	  the	  use)	  of	  human	  data	  or	  samples.
15.	  Report	  the	  clinical	  trial	  registration	  number	  (at	  ClinicalTrials.gov	  or	  equivalent),	  where	  applicable.
16.	  For	  phase	  II	  and	  III	  randomized	  controlled	  trials,	  please	  refer	  to	  the	  CONSORT	  flow	  diagram	  (see	  link	  list	  at	  top	  right)	  
and	  submit	  the	  CONSORT	  checklist	  (see	  link	  list	  at	  top	  right)	  with	  your	  submission.	  See	  author	  guidelines,	  under	  
‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  submitted	  this	  list.
17.	  For	  tumor	  marker	  prognostic	  studies,	  we	  recommend	  that	  you	  follow	  the	  REMARK	  reporting	  guidelines	  (see	  link	  list	  at	  
top	  right).	  See	  author	  guidelines,	  under	  ‘Reporting	  Guidelines’.	  Please	  confirm	  you	  have	  followed	  these	  guidelines.
18:	  Provide	  a	  “Data	  Availability”	  section	  at	  the	  end	  of	  the	  Materials	  &	  Methods,	  listing	  the	  accession	  codes	  for	  data	  
generated	  in	  this	  study	  and	  deposited	  in	  a	  public	  database	  (e.g.	  RNA-­‐Seq	  data:	  Gene	  Expression	  Omnibus	  GSE39462,	  
Proteomics	  data:	  PRIDE	  PXD000208	  etc.)	  Please	  refer	  to	  our	  author	  guidelines	  for	  ‘Data	  Deposition’.
Data	  deposition	  in	  a	  public	  repository	  is	  mandatory	  for:	  
a.	  Protein,	  DNA	  and	  RNA	  sequences	  
b.	  Macromolecular	  structures	  
c.	  Crystallographic	  data	  for	  small	  molecules	  
d.	  Functional	  genomics	  data	  
e.	  Proteomics	  and	  molecular	  interactions
19.	  Deposition	  is	  strongly	  recommended	  for	  any	  datasets	  that	  are	  central	  and	  integral	  to	  the	  study;	  please	  consider	  the	  
journal’s	  data	  policy.	  If	  no	  structured	  public	  repository	  exists	  for	  a	  given	  data	  type,	  we	  encourage	  the	  provision	  of	  
datasets	  in	  the	  manuscript	  as	  a	  Supplementary	  Document	  (see	  author	  guidelines	  under	  ‘Expanded	  View’	  or	  in	  
unstructured	  repositories	  such	  as	  Dryad	  (see	  link	  list	  at	  top	  right)	  or	  Figshare	  (see	  link	  list	  at	  top	  right).
20.	  Access	  to	  human	  clinical	  and	  genomic	  datasets	  should	  be	  provided	  with	  as	  few	  restrictions	  as	  possible	  while	  
respecting	  ethical	  obligations	  to	  the	  patients	  and	  relevant	  medical	  and	  legal	  issues.	  If	  practically	  possible	  and	  compatible	  
with	  the	  individual	  consent	  agreement	  used	  in	  the	  study,	  such	  data	  should	  be	  deposited	  in	  one	  of	  the	  major	  public	  access-­‐
controlled	  repositories	  such	  as	  dbGAP	  (see	  link	  list	  at	  top	  right)	  or	  EGA	  (see	  link	  list	  at	  top	  right).
21.	  Computational	  models	  that	  are	  central	  and	  integral	  to	  a	  study	  should	  be	  shared	  without	  restrictions	  and	  provided	  in	  a	  
machine-­‐readable	  form.	  	  The	  relevant	  accession	  numbers	  or	  links	  should	  be	  provided.	  When	  possible,	  standardized	  
format	  (SBML,	  CellML)	  should	  be	  used	  instead	  of	  scripts	  (e.g.	  MATLAB).	  Authors	  are	  strongly	  encouraged	  to	  follow	  the	  
MIRIAM	  guidelines	  (see	  link	  list	  at	  top	  right)	  and	  deposit	  their	  model	  in	  a	  public	  database	  such	  as	  Biomodels	  (see	  link	  list	  
at	  top	  right)	  or	  JWS	  Online	  (see	  link	  list	  at	  top	  right).	  If	  computer	  source	  code	  is	  provided	  with	  the	  paper,	  it	  should	  be	  
deposited	  in	  a	  public	  repository	  or	  included	  in	  supplementary	  information.
22.	  Could	  your	  study	  fall	  under	  dual	  use	  research	  restrictions?	  Please	  check	  biosecurity	  documents	  (see	  link	  list	  at	  top	  
right)	  and	  list	  of	  select	  agents	  and	  toxins	  (APHIS/CDC)	  (see	  link	  list	  at	  top	  right).	  According	  to	  our	  biosecurity	  guidelines,	  













We	  specified	  all	  antibodies	  used	  in	  the	  material	  and	  methods	  section.
HEK	  cells	  were	  purchased	  from	  the	  German	  Collection	  of	  Microorganisms	  and	  Cell	  Cultures	  (DSMZ)	  
and	  routinely	  tested	  for	  mycoplasma	  contamination	  twice	  a	  year.
We	  reported	  all	  information	  in	  the	  material	  and	  methods	  section.
All	  experiments	  were	  carried	  out	  according	  to	  the	  German	  Animal	  Protection	  Law	  and	  in	  
accordance	  with	  the	  guidelines	  for	  Animal	  Care	  of	  the	  University	  of	  Kiel	  Vote	  No.:	  V242-­‐7224.121-­‐
33	  (99-­‐7/13)	  and	  (156-­‐11/13).	  
We	  confirm	  compliance.
G-­‐	  Dual	  use	  research	  of	  concern
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